Acumen Pharmaceuticals, Inc.ABOSNASDAQ
Loading
PB Ratio: Premium ValuationElevated
Percentile Rank40
3Y CAGR-20.9%
Studio
Year-over-Year Change

Price-to-book ratio

3Y CAGR
-20.9%/yr
Annual compound
Percentile
P40
Within normal range
vs 3Y Ago
0.5x
Contraction
Streak
2 yr
Consecutive declineElevated
PeriodValueYoY Change
20240.57-18.6%
20230.70-39.9%
20221.16+1.1%
20211.15+103.7%
2020-30.98+38.6%
2019-50.43-